Minerva's stock (NASDAQ) rocketed following the release of topline Phase IIb data for schizophrenia drug MIN-101 – leaping up from its closing price of $3.55 per share on May 25 to a peak of $13.16 per share the following day. Its previous highest price in the last year was just $6.84 per share.
Minerva Rockets On Positive PhIIb Data – Is A Big Pharma Partnership On The Horizon?
Minerva Neurosciences Inc.'s schizophrenia drug that targets patients with negative symptoms, an indication with high unmet need and no approved treatments, has met primary and secondary endpoints in a Phase IIb trial – positioning the company well for access to an open market and marking it as an attractive M&A target.
More from Clinical Trials
More from R&D
• By
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
• By
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
• By
Multi-blockbuster falls short in a giant cell arteritis study.